Patients with amblyopia had a statistically significant improvement in their visual acuity after binocular rehabilitation ...

THERANEXUS company press release from Update on the Theranexus' Batten-1 project in CLN3 Batten's disease A communication by ...

A communication by BBDF and Theranexus of the promising results of the Batten-1 Phase I/II trial at the Child Neurology Society Annual Meeting in San Diego (California) Additional expanded use ...

Eyenovia (EYEN) announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its ...

The failure of Eyenovia's CHAPERONE study has seen the company’s stock value drop drastically as it considers options and ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and ...

found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years. CHAPERONE is Eyenovia's Phase 3 study evaluating its proprietary drug ...

Bitmap Books is a video game book publisher with a design-first mindset. This means that Bitmap's founder, creative ...

CVI is a spectrum of visual impairments caused by an underlying brain abnormality that affects the development of visual ...

Combining patching with active amblyopia interventions, such as vision therapy or perceptual learning, improves visual outcomes.

Experts convened by the National Institutes of Health (NIH) have identified five elements of a brain-based condition that has ...